1 not yet recruiting, 1 withdrawn. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Withdrawn 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Alli® 60 mg: new trials by email Literature Review of Alli® 60 mg trials Research Report on Alli® 60 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial With EMP16 in Preparation for Late Phase Studies EMP16-02 120 mg orlistat/40 mg acarbose, Alli® 60 mg, Vi-Siblin® S - Overweight or Obese, Obesity and Overweight | Phase 2 | Not yet recruiting | Empros Pharma AB | 39 | 2025-05-20 | 2025-05-28 |
| Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union. Alli® 60 mg - Weight Loss | Not applicable | Withdrawn | GlaxoSmithKline | 2015-12-01 | 2016-06-30 |
Obesity (1) · Overweight (1) · Weight Loss (1)
Empros Pharma AB (1) · GlaxoSmithKline (1)